A CRISPR template that adapts to your lab's targets.

This CRISPR Cas9 editing template ships configured for targeted editing of the BCL11A erythroid enhancer in HEK293T cells using Cas9 ribonucleoprotein (RNP) electroporation, with a 10-step protocol covering sgRNA design through ICE-Sanger verification of editing efficiency. The protocol assumes Lonza 4D-Nucleofector with SF cell line kit, 5 µg recombinant SpCas9 + 100 pmol synthetic sgRNA pre-complexed at room temperature, 200,000 HEK293T cells per nucleofection, T7E1 mismatch detection 72 hours post-edit, plus PCR-Sanger sequencing of the locus with ICE (Synthego) deconvolution.

Structured fields capture target, guide, delivery, and verification metadata in typed inputs (target gene, sgRNA sequence, sgRNA name, PAM, cell line, delivery method, Cas9 source, electroporation program, editing efficiency, T7E1 cleavage, ICE indel score, clone genotype), so editing outcomes are queryable across guides and cell lines instead of buried in free text. Cas9 protein, synthetic sgRNA, electroporation reagents, and PCR primers link to the ELabELN inventory so lot numbers and design references flow into every edit record without manual entry. The spreadsheet editor captures the indel spectrum (insertion, deletion sizes, frequencies) from ICE or amplicon-NGS analysis for cross-guide comparison.

The template is intended as a tested baseline for academic, biotechnology, and pharmaceutical labs running gene knockouts, knock-ins, point mutations, base editing, prime editing, or CRISPR screens. Configure the target gene, swap the sgRNA design, change the cell line and delivery method (electroporation, lipofection, viral), adjust the Cas9 variant (WT, dCas9, base editor, prime editor), or move from single-target to library screening by editing the guide and analysis sections. ELabELN's tamper-evident audit trail captures every guide-design choice, every electroporation, and every editing-efficiency call, so the resulting record supports reproducibility documentation, biosafety committee review, and FDA 21 CFR Part 11 review when the lab's quality system requires it.